Videos

Full results of the PRODROME trial, published last week in The Lancet, confirm that ubrogepant 100 mg taken during the prodromal phase of migraine can prevent the onset of moderate or severe headache within 24 hours and 48 hours after administration, and reduce functional disability and development of headache of any intensity within 24 hours …

이미지 교수는 한국 의사들이 구조적 및 기능적 연결성 연구를 포함하여, 두통 병태생리, 진단, 치료의 다양한 측면에 대한 연구를 활발히 하고 있다고 말합니다. 한국 의사들은 또한 두통 질환의 다기관 등록을 통해 협력하고 있습니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into …

이미지 교수는 편두통 및 관련 장애에 대한 더 큰 인식이 한국에서 필요하다고 제안하며, 편두통 전문가가 충분하지 않은 상황에서 더 많은 비전문가 의사들이 편두통 환자들을 돌보는데 관심을 가지기를 희망합니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the …

이미지 교수는 편두통 환자를 치료하는 의사들에게, 특히 치료가 어려운 환자의 경우, 기본 원칙으로 돌아가라고 조언하고, CGRP 단클론항체를 사용하는 치료 기간에 대한 유연한 접근 방식에 대해 논의합니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the performance of …

Korean physicians are active in research into many aspects of headache pathophysiology, diagnosis and treatment, including structural and functional connectivity studies, says Dr Mi Ji Lee. They are also collaborating through a multi-centre registry of headache disorders.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no …

Dr Mi Ji Lee suggests that greater awareness of migraine and its associated disability are needed in Korea and, in the absence of sufficient migraine experts, she hopes that more non-specialist doctors will become interested in caring for patients with the condition.   This educational activity is supported by an educational grant from H. Lundbeck …

Dr Mi Ji Lee advises physicians treating patients with migraine to go back to basic principles, especially in difficult-to-treat patients, and discusses a flexible approach to treatment duration with CGRP monoclonal antibodies.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into …

한국 내 편두통의 엄밀한 유병률은 약 6%이고 개연 편두통 유병률은 12%로 전체 유병률은 북미 및 유럽과 비슷합니다. 한국의 편두통 역학이 몇몇 다른 나라들과 차이를 보이는 가능성 있는 이유들에 대해 이미지 교수가 논의합니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into …

한국은 잘 정립된 1차, 2차, 3차 진료 서비스를 갖추고 있지만 환자들은 편두통 진단을 받기까지 수 년을 기다려야만 할 수도 있습니다. 이미지 교수는 대중의 오해와 국제적 분류와 비교했을 때 핵심 증상의 차이가 이에 일조한다고 설명합니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or …

한국에서의 편두통 급성기 및 예방 치료를 위한 다양한 치료법과 국민건강보험 프로그램을 통한 칼시토닌 유전자 관련 펩타이드 단클론항체 (CGRP mAb)의 일부 급여에 대한 엄격한 자격 기준에 대해 이미지 교수가 설명합니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or …

한국 내 여러 센터가 CGRP 단클론항체에 대한 국제적 및 지역 임상 시험에 참여했으며, 한국 의사들도 실제 임상 연구를 수행했습니다. 도출된 결과들과 그 결과들이 임상의들과 환자들에게 의미하는 바에 대해 이미지 교수가 살펴봅니다.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the …

Several centres in Korea took part in international and regional clinical trials of CGRP monoclonal antibodies, and Korean physicians have also carried out real world studies. Dr Mi Ji Lee takes a look at the results and what they mean for clinicians and patients.   This educational activity is supported by an educational grant from …

Dr Mi Ji Lee describes the range of therapies available for acute and preventive treatment of migraine in Korea and the strict eligibility criteria for partial reimbursement of CGRP monoclonal antibodies through the national insurance programme.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence …

Korea has well defined primary, secondary and tertiary care services but patients can wait years for a migraine diagnosis. Dr Mi Ji Lee explains that public misunderstandings and differences in core symptoms compared to international classifications play a part.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has …

Strict prevalence of migraine in Korea is about 6% and probable migraine prevalence is 12% – bringing overall prevalence close to that in North America and Europe. Dr Mi Ji Lee discusses possible reasons why migraine epidemiology in Korea is different from some other countries.   This educational activity is supported by an educational grant …

Dr K Ravishankar discusses the need to educate patients about migraine so they understand the aims of treatment, and he stresses the importance of treating the disease, not just the attack.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the …

In the final video in the series, Dr K Ravishankar calls for more progress to be made in improving migraine care in India and presents a roadmap for achieving the changes that are needed.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or …

Dr K Ravishankar describes his approach to the treatment of episodic and chronic migraine, and how he addresses the challenge of patients who present with medication overuse headache.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the …

Turning to drugs used to prevent migraine attacks in India, Dr K Ravishankar discusses the range currently available to doctors and patients, and the impact of newer agents in chronic migraine.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the …

In the fifth video in the series, Dr K Ravishankar assesses the availability of drugs for the treatment of acute attacks of migraine in India, including the newer agents that doctors are hearing about.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or …

Dr K Ravishankar divides the reasons for under-diagnosis of migraine in India into patient- and physician-related issues, and explains that much depends on whether a patient can afford care.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or …

Dr K Ravishankar reviews the multiple barriers to migraine diagnosis that mean many people are unaware of the cause of their headaches and are unable to access the levels of specialist care that they need.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on …

Dr K Ravishankar describes the main migraine triggers to consider when assessing a patient in India as some are quite different from those reported in the medical literature based on studies in Europe and America.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on …

Migraine affects approximately 33 crore (330 million) people in India, and is responsible for a significant proportion of disability associated with neurological disorders, as Dr K Ravishankar explains.   This educational activity is supported by an educational grant from H. Lundbeck A/S, who has had no influence on or input into the development or the …

When discussing reimbursement for anti-CGRP therapies, clinicians can emphasise the global consensus about their impact on the daily lives of people with migraine, and how the cost/benefit relationship can be optimised, advises Professor Ramez Reda Moustafa.   < Previous page

As most patients starting anti-CGRP therapies are taking other medications, Professor Ramez Reda Moustafa discusses prescribing strategies for combining treatments including reducing, stopping or maintaining use of traditional migraine medicines.   < Previous page

عند مناقشة تسديد تكاليف العلاجات المضادة لـ CGRP ، يمكن للأطباء التأكيد على الإجماع العالمي حول تأثيرها على الحياة اليومية للأشخاص الذين يعانون من الصداع النصفي، وكيف يمكن تحسين علاقة التكلفة/الفائدة ، كما ينصح الأستاذ رامز رضا مصطفى.   < الصفحة السابقة

نظرًا لأن معظم المرضى الذين يبدأون العلاجات المضادة لـ CGRP يتناولون أدوية أخرى، يناقش البروفيسور رامز رضا مصطفى استراتيجيات الجمع بين العلاجات بما في ذلك تقليل أو وقف أو الاستمرار في استخدام أدوية الصداع النصفي التقليدية.   < الصفحة السابقة

Professor Ramez Reda Moustafa recommends that clinicians initially prescribe anti-CGRP therapies to patients who have responded poorly to other treatments and stresses the importance of continuing therapy for at least three months before assessing the effects.   < Previous page

Professor Ramez Reda Moustafa reviews the growing evidence of the benefits of CGRP monoclonal antibodies in patients with episodic or chronic migraine, with or without medication overuse headache, and in those with previous multiple treatment failures.   < Previous page

يوصي البروفيسور رامز رضا مصطفى بأن يصف الأطباء في البداية علاجات مضادة لـ CGRP للمرضى الذين لا يستجيبون بشكل جيد للعلاجات الأخرى ويؤكد على أهمية استمرار العلاج لمدة ثلاثة شهور على الأقل قبل تقييم التأثير.   < الصفحة السابقة

يستعرض البروفيسور رامز رضا مصطفى الأدلة المتزايدة على فوائد الأجسام المضادة أحادية النسيلة CGRP في المرضى الذين يعانون من الصداع النصفي (الشقيقة) العرضي أو المزمن، مع أو بدون الصداع الناتج عن الإفراط في تناول الأدوية، وفي المرضى الذين يعانون من فشل علاجي متعدد سابقًا.   < الصفحة السابقة

Up to one in three people in the Middle East have migraine, with a significant financial, educational and social burden. As Professor Ramez Reda Moustafa explains, easy availability of over-the-counter painkillers means that medication overuse headache is common.   < Previous page

Professor Ramez Reda Moustafa discusses the impact of poor efficacy and tolerability of traditional migraine medicines on treatment adherence, and the benefits of newer migraine-specific therapies that will encourage patients to remain on treatment.     < Previous page

يعاني ما يصل إلى واحد من كل ثلاثة أشخاص في الشرق الأوسط من الصداع النصفي، مما يشكل عبئًا ماليًا وتعليميًا واجتماعيًا كبيرًا. وكما يوضح البروفيسور رامز رضا مصطفى فإن سهولة توفر المسكّنات التي لا تستلزم وصفة طبية يعني أن الصداع الناتج عن الإفراط في تناول الأدوية أمر شائع.   < الصفحة السابقة

يناقش البروفيسور رامز رضا مصطفى تأثير ضعف الفعالية والتحمل لأدوية الصداع النصفي التقليدية على عملية الالتزام بالعلاج، وفوائد العلاجات الجديدة الخاصة بالصداع النصفي (الشقيقة) التي ستشجع المرضى على الاستمرار في العلاج.   < الصفحة السابقة

Professor Fernando Kowacs proposes the type of medical report that is needed to achieve a successful initial application for reimbursement of CGRP monoclonal antibodies for a patient, and how this can be updated for continuing reimbursement success.     < Previous page

O Professor Kowacs propõe o tipo de relatório médico a ser usado para que os pacientes recebam o reembolso de tratamento com anticorpos monoclonais CGRP e como deve ser feita a atualização do relatório.     < Página anterior

Com o aumento do uso dos anticorpos monoclonais CGRP em combinação com outras terapias preventivas, como a onabotulinumtoxinaA, o Professor Kowacs discute as oportunidades para quem sofre de migrânea difícil de tratar.     < Página anterior

As CGRP monoclonal antibodies are increasingly used in combination with other preventive therapies, such as onabotulinumtoxinA, Professor Fernando Kowacs discusses the opportunities for patients with the hardest to treat migraine.     < Previous page

O Professor Fernando Kowacs considera quais pacientes podem se beneficiar dos anticorpos monoclonais CGRP e descreve os fatores que influenciam sua escolha de medicamento para cada paciente, a abordagem de acompanhamento e as estratégias de troca para quem não responde bem a eles.     < Página anterior

Professor Fernando Kowacs considers which patients may benefit from CGRP monoclonal antibodies and describes the factors that influence his choice of drug for individual patients as well as his approach to follow up, and his switching strategies for poor responders.     < Previous page

Há cada vez mais evidências que apoiam a eficácia, a segurança e a tolerabilidade dos anticorpos monoclonais CGRP. O Professor Fernando Kowacs revisa alguns dos principais achados de ensaios clínicos e relata evidências do mundo real publicadas por médicos no Brasil.      < Página anterior

O Professor Fernando Kowacs explica que alguns pacientes esperam anos pelo diagnóstico correto e enfatiza a necessidade de maior disponibilidade de terapias eficazes preventivas e agudas de migrânea, incluindo anticorpos monoclonais CGRP.      < Página anterior

Uma em cada cinco mulheres e um em cada 10 homens sofrem de migrânea no Brasil, com níveis significativos de incapacidade. O Professor Fernando Kowacs discute a prevalência de migrânea no Brasil e os tipos de tratamento disponíveis.      < Página anterior

A growing body of evidence supports the efficacy, safety and tolerability of CGRP monoclonal antibodies. Professor Fernando Kowacs reviews some of the key clinical trial findings and reports real world evidence published by clinicians in Brazil.     < Previous page

Professor Fernando Kowacs explains that some patients wait years before they are correctly diagnosed with migraine, and stresses the need for wider availability of effective preventive and acute migraine therapies, including CGRP monoclonal antibodies.     < Previous page

Approximately one in five women and one in 10 men suffer from migraine in Brazil, with significant levels of disability. Professor Fernando Kowacs discusses the prevalence of migraine in Brazil and the types of treatment available for patients.     < Previous page

As CGRP monoclonal antibodies (mAbs) are rarely 100% effective at preventing migraine, clinicians are starting to combine them with gepants to treat breakthrough headaches. Richard Lipton, Edwin S Lowe Professor of Neurology at the Albert Einstein College of Medicine, New York, USA, explains that there is a growing body of evidence from pharmacokinetic and observational …

For Patricia Pozo-Rosich, 2020 was an important year for patients with migraine, especially in Spain where she works. With access to anti-CGRP therapies becoming available for the first time, neurologists were able to educate their patients about the new agents and start to see the effects in clinical practice. Clinical trial data published in 2020 …